Cited 0 times in
Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.